While the maintenance of an Outperform rating suggests Baird's continued confidence in EyePoint Pharmaceuticals' potential, the reduction in the price target could reflect adjustments in valuation metrics or market conditions. This mixed signal might lead to short-term uncertainty among investors, potentially stabilizing the stock price as the market digests the news.